Octagam Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of plasma collection infrastructure, increasing diagnosis of primary immunodeficiencies, clinical acceptance of ivig therapies, rising hospital-based infusion treatments, improved plasma fractionation techniques.

The growth in the forecast period can be attributed to growing prevalence of autoimmune and neurological disorders, increasing use in transplant-related complications, expansion of home infusion services, advancements in plasma processing technology, rising investments in immunotherapy research. Major trends in the forecast period include increasing use of ivig in autoimmune disorders, rising demand for plasma-derived therapies, expansion of immunodeficiency treatment applications, enhanced safety through pathogen reduction, growing focus on standardized immunoglobulin products.

The increasing prevalence of immunodeficiency disorders is expected to drive the growth of the Octagam market in the coming years. Immunodeficiency disorders are conditions in which the immune system fails to mount an adequate response to foreign pathogens or the body’s own tissues, resulting in autoimmune conditions or reduced ability to fight infections. The rise in immunodeficiency disorders is attributed to factors such as exposure to environmental toxins, lifestyle changes, and genetic predispositions that alter immune function. Octagam supports patient health by delivering immunoglobulin therapy for individuals with primary immunodeficiency diseases, helping to prevent infections and manage immune system dysfunction. For example, in December 2024, the U.S. Department of Health & Human Services reported that in 2023, approximately 39.9 million people worldwide were living with HIV, including 38.6 million adults aged 15 and older and 1.4 million children under the age of 15, with women and girls accounting for around 53% of cases. Therefore, the growing incidence of immunodeficiency disorders is contributing to the expansion of the Octagam market.

Rising healthcare expenditure is also expected to propel the growth of the Octagam market. Healthcare expenditure refers to the financial resources allocated to the delivery of healthcare services, including medical treatments, facilities, workforce, and equipment. Growth in healthcare spending is driven by factors such as an aging population, increasing prevalence of chronic diseases, technological advancements in medicine, and higher expectations for quality care. Increased healthcare expenditure supports the demand for plasma-derived therapies such as Octagam by expanding market access and improving patient availability to essential treatments. For instance, in April 2025, the American Medical Association reported that U.S. health spending increased by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person, compared with a 4.6% increase in 2022. As a result, rising healthcare expenditure is driving the growth of the Octagam market.

Major companies operating in the Octagam market are focusing on strengthening supply resilience through initiatives such as high-concentration intravenous immunoglobulin product profile synopses to improve clinical clarity and regulatory alignment. A high-concentration intravenous immunoglobulin product profile synopsis is a structured technical overview that outlines the key characteristics, clinical specifications, and safety attributes of a concentrated IVIg formulation. For example, in March 2025, Octapharma, a Switzerland-based plasma products company, launched Gamten 10% IVIg, a 10% human normal immunoglobulin solution produced using UK-sourced plasma. The product enhances self-sufficiency, retains the same formulation and clinical profile as Octagam 10%, and offers high purity with at least 95% IgG content and IgA levels of no more than 0.4 mg/ml.

Major companies operating in the octagam market are Octapharma AG.

North America was the largest region in the octagam market in 2025. The regions covered in the octagam market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the octagam market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the octagam market by increasing costs of imported plasma fractionation equipment, sterile processing materials, infusion packaging, and cold-chain logistics services. Europe and North America are most affected due to cross-border plasma sourcing and centralized manufacturing hubs, while other regions face constrained access due to higher import costs. These tariffs raise treatment costs and procurement complexity for hospitals. However, they also support regional plasma processing investments, localized fractionation capacity, and strengthened supply security for critical IVIG therapies.

The octagam market research report is one of a series of new reports that provides octagam market statistics, including octagam industry global market size, regional shares, competitors with a octagam market share, detailed octagam market segments, market trends and opportunities, and any further data you may need to thrive in the octagam industry. This octagam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Octagam is a brand of immune globulin intravenous (IVIG) therapy derived from human plasma. It is used to treat immune deficiencies and certain autoimmune conditions by providing a concentrated dose of antibodies to help strengthen or regulate the immune system. Octagam is administered via intravenous infusion and is typically used under the supervision of healthcare professionals.

The primary indications for Octagam include primary humoral immunodeficiency, chronic immune thrombocytopenic purpura, dermatomyositis, bone marrow transplantation, and AIDS. Primary humoral immunodeficiency refers to a group of genetic disorders characterized by the absence or dysfunction of antibodies, which leads to an increased susceptibility to infections. The formulations available are 5% and 10% liquid preparations, which are distributed through pharmacies and online pharmacies.

The octagam market consists of sales of pre-filled syringes, vials, infusion kits, infusion pumps, and tubing. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.